Better Health Whole Wellness Center
- Ketamine Therapy
- Psychedelic Therapy
- Erectile Dysfunction (ED) Treatment
Philadelphia, PA
Psychedelic-assisted therapy in Philadelphia sits mostly in the ketamine-assisted psychotherapy category, with some clinics also preparing for state-specific psilocybin frameworks. Psychiatric referrals for complex cases route through Penn Medicine, Jefferson Health, Temple Health, and CHOP. Demand reflects a dense academic-medicine and healthcare-industry population.
Ketamine-assisted psychotherapy has the strongest US evidence base among psychedelic modalities. Psilocybin is not FDA approved and is only legally accessible within research or specific state programs. MDMA therapy is investigational. Clinics in Philadelphia, Pennsylvania should be evaluated for therapist training, safety protocols, and honest evidence framing. Pennsylvania rules on delegation, collaborative practice, and compounding determines what can legally be offered.
With psychedelic therapy clinics on Regenerated.com in Philadelphia, patients can compare clinician training, integration support, and legal framework before booking.
Regulatory context
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
Pennsylvania enforces federal scheduling. The Pennsylvania State Board of Medicine oversees prescriber conduct. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth rules. Pennsylvania PDMP requires controlled substance reporting.